These results implicate the necessity of cholesterol-enriched domains in survival of TAMR cells and suggest that agents that can disrupt cholesterol-enriched domains have potential as a promising strategy to circumvent TAMR when combined with TAM in ER+ breast cancer. This evidence concerns the gene ESR1 and breast cancer.